This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia
BMC Cancer Open Access 18 February 2021
-
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
Annals of Hematology Open Access 20 September 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–4588.
Mahindra A, Bolwell B, Sobecks R, Rybicki L, Pohlman B, Dean R et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009; 146: 310–316.
Platzbecker U, Bornhauser M, Germing U, Stumpf J, Scott BL, Kroger N et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008; 14: 1217–1225.
Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799–805.
Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110: 1303–1306.
Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T . Non-transferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol 2001; 113: 836–838.
Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW . Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73: 403–409.
Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 852–860.
Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009; 114: 3064–3073.
Fukushima T, Kawabata H, Nakamura T, Iwao H, Nakajima A, Miki M et al. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res 2011; 31: 1741–1744.
Acknowledgements
This work was funded in part by the Jock and Bunny Adams Research and Education Endowment, and the National Institutes of Health, CA142106-06. PA is a recipient of a Special Fellowship in Clinical Research from the Leukemia and Lymphoma Society, a Career Development Award from the Conquer Cancer/ASCO Foundation, and a Scholar Award from the American Society of Hematology. PA and EJN have received research funding from Novartis, and EJN has also received research funding from FerroKin Biosciences.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Armand, P., Sainvil, MM., Kim, H. et al. Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant 48, 146–147 (2013). https://doi.org/10.1038/bmt.2012.94
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.94
This article is cited by
-
Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia
BMC Cancer (2021)
-
Iron overload in the HCT patient: a review
Bone Marrow Transplantation (2021)
-
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
Annals of Hematology (2016)
-
Deferoxamine
Reactions Weekly (2013)